AntiCancer to test its methioninase as a new treatment for coronavirus
Category: #health  By Mateen Dalal  Date: 2020-02-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

AntiCancer to test its methioninase as a new treatment for coronavirus

The threat of coronavirus needs to be addressed as early as possible, particularly since there are no particular treatments or vaccines currently available for patients suffering from coronavirus globally. As the count of patients infected by the 2019-nCoV reaches 10,000 and death toll hits the 200 mark, with both these numbers rapidly growing, without any particular vaccination for at least one year, the situation is turning dire.

AntiCancer Inc, a US-based biopharmaceutical company, reportedly announced its plans to test its methionine as a treatment for the Coronavirus, the current outbreak of the disease is widely spreading across China and steadily making its way around the world.

AntiCancer’s oral recombinant methioninase specifically targets circulating methionine in the patient’s body. Methionine is a type of amino acid that is derived from food that is rich in protein. Oral methioninase has proven to be highly capable of treating cancer, diabetes, and obesity by limiting methionine in the body.

It is proved that virally infected cells are destroyed by methionine restriction. More importantly, coronaviruses have a particular requirement for methionine to replicate and be able to evade the host’s immune system.

Methioninase project leader at AntiCancer, Dr. Qinghong Han stated that oral recombinant methioninase has the capability to reduce or arrest infection of coronavirus (2019-nCoV) in patients, without and with symptoms.

Han further added that the company would first test methioninase with cultured lung cells that are infected by the 2019-nCoV in vitro. After this, the second test would assess the oral recombinant methioninase in patients infected by the virus.

AntiCancer would conduct all these trials in China together with appropriate organizations as well as safety profiles. Oral recombinant methioninase would be an effective treatment for 2019-nCoV disease as coronaviruses also have a special demand for methionine, Han added.

AntiCancer would partner with AntiCancer Beijing, its sister company located in Beijing, in order to develop oral recombinant methioninase for coronavirus (2019-nCoV) in China. AntiCancer is a San Diego based company and its subsidiaries are in Seoul, Tokyo, Nanjing, and Beijing.

 

Source credit: https://www.streetinsider.com/Business+Wire/AntiCancer+Inc.+to+Target+Its+Oral+Recombinant+Methioninase+Against+2019-nCoV+Coronavirus/16402763.htm

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

DealerSocket closes acquisition of Auto/Mate to offer innovative DMS
DealerSocket closes acquisition of Auto/Mate to offer innovative DMS
By Mateen Dalal

DealerSocket, a customer relationship management solutions provider, has recently completed the acquisition of DMS provider Auto/Mate to offer an all-in-one innovative software for their dealerships. Auto/Mate is a leading company that develops and m...

EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G
EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G
By Mateen Dalal

The European Union and the United States are likely to partner to counter the increasing dominance of Chinese tech giant, Huawei Technologies on next generation 5G telecommunications technology. However, this partnership will reportedly only come int...

CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
By Mateen Dalal

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to offer therapy for around 22 various...